NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics […]
Second randomized, double-blind, placebo-controlled Phase 2 trial confirms multi-lineage myelopreservation benefits of trilaciclib in first-line small cell lung cancer (1L […]
Pivotal Partners and Pilgrim Consulting add Payment Data Systems’ best-in-class payments facilitation technology to their current solution set SAN ANTONIO, […]